Skip to main content

Table 4 Cox regression analyses in two subgroups divided by the median HER2 expression value.

From: Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

Cohort subset>

Variable

Hazard ratio

95%C.I.

P-value

Log10HER2 expression • 1.799*

Log10 HER2 expression

0.06

0.01 - 0.51

0.010

(n = 37)

Hormone receptor status

0.39

0.05 - 2.86

0.354

 

Brain mets

0.14

0.02 - 0.87

0.034

Log10HER2 expression < 1.799*

Log10 HER2 expression

16.0

1.64 - 155.9

0.017

(n = 37)

Hormone receptor status

0.20

0.03 - 1.57

0.125

 

Brain mets

0.04

0.01 - 0.28

0.001

  1. * Median (50 percentile) value of Log10HER2 expression measurements